Literature DB >> 30142109

DILUTE POVIDONE-IODINE PROPHYLAXIS MAINTAINS SAFETY WHILE IMPROVING PATIENT COMFORT AFTER INTRAVITREAL INJECTIONS.

Marc C Peden1, Mark E Hammer, Ivan J Suñer.   

Abstract

PURPOSE: To report the rates of postintravitreal injection (IVT) endophthalmitis with topical conjunctival application of various concentrations of povidone-iodine (PI), including no PI.
METHODS: Retrospective chart review of patients receiving IVTs performed in a single practice between January 2011 and June 2016. Concentration of PI for all injections was recorded and cases of endophthalmitis identified and reviewed.
RESULTS: A total of 35,060 IVTs in 1854 patients were included from the 5.5-year period. 29,281 injections were performed with standard 5% PI, 5,460 injections with diluted PI (3,731 with 2.5%, 1,673 with 1.25%, 56 with 0.625%), and 319 IVTs with no PI. Incidence of patient-reported PI sensitivity occurred in 15.9% of patients. Fourteen cases of endophthalmitis were identified: 12 in eyes that received 5% PI, one in an eye that received 1.25% PI, and one in an eye receiving no PI. The incidence of endophthalmitis was 0.04% for 5% PI, 0.02% for dilute PI, and 0.31% for no PI prophylaxis. All cases underwent prompt vitrectomy and had positive cultures for coagulase-negative Staphylococcus.
CONCLUSION: Application of dilute PI solution to the conjunctiva at the time of IVT is an effective alternative to 5% PI for endophthalmitis prophylaxis in betadine-sensitive patients.

Entities:  

Year:  2019        PMID: 30142109     DOI: 10.1097/IAE.0000000000002290

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.

Authors:  Ellen Shorter; Meredith Whiteside; Jennifer Harthan; Mathew S Margolis; Andrew T Hartwick; Spencer Johnson; Mary Migneco; Christina Morettin; Christian K Olson; Julia Huecker; Tammy Than; Mae O Gordon
Journal:  Ocul Surf       Date:  2019-08-08       Impact factor: 5.033

2.  Povidone iodine treatment is deleterious to human ocular surface conjunctival cells in culture.

Authors:  William Swift; Jeffrey A Bair; Wanxue Chen; Michael Li; Sole Lie; Dayu Li; Menglu Yang; Marie A Shatos; Robin R Hodges; Miriam Kolko; Tor P Utheim; Wendell Scott; Darlene A Dartt
Journal:  BMJ Open Ophthalmol       Date:  2020-09-16

3.  The effect of diluting povidone-iodine on bacterial growth associated with speech.

Authors:  Sivashanth Gnanasekaran; Sophie Rogers; Sanj Wickremasinghe; Sukhpal S Sandhu
Journal:  BMC Ophthalmol       Date:  2019-02-26       Impact factor: 2.209

4.  Survey of Intravitreal Injection Techniques Among Retina Specialists in Mexico.

Authors:  Andree Henaine-Berra; Vanesa Flores-Peredo; Gabriela Lopezcarasa-Hernandez; Maria Ana Martinez-Castellanos; Ximena Mira-Lorenzo; Adriana Solis-Vivanco; Gerardo Garcia-Aguirre
Journal:  Clin Ophthalmol       Date:  2020-11-26

5.  The Antibacterial Comparison of 5% and 2.5% Povidone Iodine to 0.01% Hypochlorous Acid Using Corneoscleral Tissue as a Solid-Phase Medium.

Authors:  Regis Kowalski; Roheena Kamyar; Michelle Rhee; Alex Mammen; Deepinder Dhaliwal; Eric G Romanowski; Vishal Jhanji; Andrew W Eller
Journal:  Clin Ophthalmol       Date:  2021-09-01

6.  Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic.

Authors:  Koji Tanaka; Hiroyuki Shimada; Ryusaburo Mori; Yorihisa Kitagawa; Hajime Onoe; Kazuki Tamura; Hiroyuki Nakashizuka
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.241

7.  In vivo antimicrobial activity of 0.6% povidone-iodine eye drops in patients undergoing intravitreal injections: a prospective study.

Authors:  Daniele Tognetto; Marco R Pastore; Lorenzo Belfanti; Riccardo Merli; Alex L Vinciguerra; Marina Busetti; Giulia Barbati; Gabriella Cirigliano
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

8.  Hypochlorous acid antiseptic washout improves patient comfort after intravitreal injection: A patient reported outcomes study.

Authors:  Anthony Fam; Paul T Finger; Ankit S Tomar; Gaurav Garg; Kimberly J Chin
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.